Dehydration News and Research

Latest Dehydration News and Research

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

Haiti's cholera outbreak appears to have spread to its capital, "imperiling nearly 3 million people living in Port-au-Prince, nearly half of them in unsanitary tent camps for the homeless from the Jan. 12 earthquake," the Associated Press/KIRO reports.

10 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Breast Cancer Awareness month spotlights the increasingly high incidence of breast cancer, and also brings attention to the question, "what is being done to speed and ease recovery?"

26 Oct 2010

Authors highlight importance of body fluid recovery after training session in sports persons

Top sports persons must always perform to their maximum capacity, making them the most vulnerable to the effects of dehydration. Now, a new study conducted by researchers from the Universidad de Castilla la Mancha (UCLM) reveals that 91% of professional basketball, volleyball, handball and football players are dehydrated when they begin their training sessions.

19 Oct 2010

Scientists to monitor effectiveness of Streptococcus vaccine

Respiratory infections and diarrhoeal diseases kill approximately four million children each year, with most deaths occurring in developing countries. New vaccines for Streptococcus pneumoniae, a bacterium that causes pneumonia, and rotavirus, the most common cause of severe diarrhoea, have proved successful in preventing the development of the diseases in clinical trials, but have yet to be used routinely in many parts of Africa.

15 Oct 2010

Administering ondansetron drug to children is economically advantageous

Two years ago, a study by University of North Carolina at Chapel Hill researchers found that an anti-vomiting drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.Now a new economic analysis led by Canadian researchers, in collaboration with Michael J. Steiner, MD, assistant professor of pediatrics at UNC, concludes that routinely giving ondansetron to children with gastroenteritis-induced vomiting would prevent thousands of hospitalizations and save millions of dollars each year.

15 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.

11 Oct 2010

Trekkers and climbers face high risk for Acute Mountain Sickness

Climbers of high peaks such as Mount Kilimanjaro are at high risk for Acute Mountain Sickness (AMS). Trekkers should not ignore AMS warning signs, which can progress to more serious medical outcomes.

7 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

CPS recommends all Canadian babies should be vaccinated against rotavirus

All Canadian babies should be vaccinated against rotavirus, according to a new statement by the Canadian Paediatric Society. The CPS is also calling for public funding of the vaccine, which is not currently covered by provincial or territorial health plans.

5 Oct 2010

Suspected hand, foot and mouth disease on Denver flight

Two children arrived on a flight from Mexico to Denver showing symptoms of the contagious illness called ‘hand, foot and mouth’ disease (HFMD) and were checked by paramedics. They were allowed to leave after experts said they were no threat to public health.

4 Oct 2010

'Intraluminal protection' IV needleless connector more effective in preventing CLABSIs: Study

A lengthy study performed at Methodist Extended Care Hospital resulted in the elimination of potentially deadly infections. The study findings were reported in a scientific poster presentation at the recent annual meeting of the Association for Vascular Access (AVA), a leading national organization focusing on patient safety and best nursing practices.

30 Sep 2010

Dual eligible patients more likely to be hospitalized than Medicare beneficiaries: AHRQ

Americans who were eligible for coverage under both Medicare and Medicaid in 2008 were hospitalized for bed sores, asthma and diabetes at more than twice the rate of other Medicare beneficiaries, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

27 Sep 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

Oxygen Biotherapeutics announces CRADA Agreement amendment

Oxygen Biotherapeutics, Inc. today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.

20 Sep 2010

Researchers identify new target for cystic fibrosis

The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Dehydration News and Research

Latest Dehydration News and Research

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Authors highlight importance of body fluid recovery after training session in sports persons

Scientists to monitor effectiveness of Streptococcus vaccine

Administering ondansetron drug to children is economically advantageous

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Allos announces favorable survival data from FOLOTYN Phase 2b study

Trekkers and climbers face high risk for Acute Mountain Sickness

Amgen to present oncology portfolio results at ESMO Congress

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Amgen announces PRIME '203' and '181' Phase 3 trial results

CPS recommends all Canadian babies should be vaccinated against rotavirus

Suspected hand, foot and mouth disease on Denver flight

'Intraluminal protection' IV needleless connector more effective in preventing CLABSIs: Study

Dual eligible patients more likely to be hospitalized than Medicare beneficiaries: AHRQ

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

Oxygen Biotherapeutics announces CRADA Agreement amendment

Researchers identify new target for cystic fibrosis

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Dehydration News and Research

Latest Dehydration News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in